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Introduction
The endothelins are vasoactive peptides of which up to
now three different isopeptides have been identified.
Endothelin-1 (ET-1) is a potent vasoconstrictor produced
by endothelial cells [1]. In the kidney it is produced both
in endothelial and in non-endothelial cells [2]. No storage
granules of ET-1 have been discovered thus far and
approximately 25% of ET-1 synthesized is secreted into
the general circulation [3]. Endothelins have been thought
to have a considerable impact on the vascular tone both
in normal physiological and in diseased states. How-
ever, plasma endothelin levels have not been found to 
be elevated in essential hypertension [4,5]. Endothelin
levels are elevated in pulmonary hypertension and renal
failure [5,6]. Because vasoactive substances take such an
important part in the pathophysiology of renovascular 
hypertension (RVH), it is worth considering whether
endothelins are involved in at least some of the vascular
reactivity mechanisms operating in this form of high blood
pressure.
Specific information about the role of endothelin in RVH
is, however, incomplete. Several findings suggest that
endothelin could be involved in RVH through involve-
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Endothelin and active renin levels in essential hypertension
and hypertension with renal artery stenosis before and after
percutaneous transluminal renal angioplasty
Kim Edwards Teunissen, Cornelis T. Postma, Brigit C. van Jaarsveld*, 
Frans H.M. Derkx* and Theo Thien
Objective To determine whether active renin and
endothelin levels in venous plasma differ between
patients with renal artery stenosis and patients with
primary hypertension. Among the patients with renal
artery stenosis we also compared active renin and
endothelin levels between subjects who had been cured
or whose blood pressure had improved after treatment of
the stenosis and those without a beneficial reaction after
such treatment.
Methods We measured immunoreactive endothelin and
active renin levels in peripheral venous plasma before
and 1 h after angiotensin converting enzyme inhibition in
25 patients with primary hypertension and in 27 patients
with hypertension and renal artery stenosis.
Percutaneous transluminal angioplasty was performed in
21 patients of the latter group. For 11 patients of this
group, hypertension was cured or there was an
improvement, whereas 10 other patients did not respond
to this treatment. Baseline active renin and endothelin
levels were compared between these groups, as were
the clinical characteristics of the patients.
Results Baseline endothelin levels were similar in
members of the renal artery stenosis [median 3.6 pg/ml
(range 1.4–11.7)] and in members of the no stenosis
group [5.0 pg/ml (1.5–8.0)]. Also baseline endothelin
levels did not differ between members of the
successfully treated [3.6 pg/ml (1.8–8.9)] and
unsuccessfully treated groups [3.75 pg/ml (1.4–8.3)].
Angiotensin converting enzyme (ACE) inhibition failed to
cause a significant change in endothelin level in
members of any of the patient groups. Although baseline
renin levels differed significantly between members of
the renal artery stenosis and no stenosis groups
[40.2 mu/ml (0.9–543) versus 13.4 mu/ml (2.5–931),
(P < 0.05)], there was no difference in baseline renin
levels between the members of successful and
unsuccessful groups [25.7 mu/ml (9.2–475.6) versus
65.3 mu/ml (12.3–542.6)]. ACE inhibition caused a
significant increase in renin level in members of all
groups except the unsuccessfully treated group.
Conclusions Circulating endothelin levels did not differ
significantly among patients with essential hypertension,
hypertension with renal artery stenosis and proven
renovascular hypertension and, although the
renin–angiotensin system was clearly activated in
members of the renovascular hypertension group, ACE
inhibition did not affect their endothelin levels. These
results suggest that endothelin does not play a direct
role in the pathophysiology of renovascular hypertension.
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ment with the renin–angiotensin system. First, endothe-
lial cell culture studies have shown that hypoxia [7] and
angiotensin II (Ang II) induce synthesis and release of
endothelin [8]. Angiotensin converting enzyme (ACE)
inhibition attenuates this release [9]. Second, Ang II stim-
ulates endothelial production of endothelin and thereby
potentiates contractions in response to noradrenaline in
mesenteric resistance arteries of spontaneously hyper-
tensive rats [10]. Furthermore, Sventek et al. [11] found
vascular overexpression of ET-1 gene in one-kidney, one
clip hypertensive rats but only during the late phase of
two-kidney, one clip hypertensive rats. Also several 
clinical studies have been reported but they produced
contradictory results in which endothelin levels were
found to be either normal or elevated in patients with
renal artery stenosis (RAS) [12–15].
The aim of the present study was to investigate a poss-
ible role of endothelin in the pathophysiology of RVH in
humans. We studied endothelin and renin levels in
peripheral venous blood before and after ACE inhibition
in members of the following groups of hypertensive
patients: subjects with essential hypertension, persons
with hypertension and RAS, patients whose hypertension
was cured or alleviated by percutaneous transluminal renal
angioplasty (PTRA) treatment of RAS and patients whose
hypertension was not lessened by PTRA treatment of
RAS.
In studying these specific patient groups, we supposed
that we would be able to employ ACE inhibition and
responses to PTRA as tools to select out RAS patients
with true RVH, allowing us to compare endothelin levels
of these renovascular hypertensives with those of other
hypertensives. Given the evidence on endothelin summa-
rized above, we hypothesized that ACE inhibition would
cause not only an increase in renin levels but also, via a
decrease in Ang II levels, a decrease in circulating
endothelin levels in patients with RVH. Furthermore, the
renin : endothelin level ratio before and after ACE inhi-
bition could provide a reliable marker for distinguishing
true RVH from essential hypertension cases with and
without RAS.
Patients and methods
For 52 hypertensive patients newly referred to the out-
patient clinic, the physicians in charge deemed it neces-
sary to perform intra-arterial digital subtraction angio-
graphy. Indications for angiography were treatment-resis-
tant hypertension, defined as blood pressure values above
160/90 mmHg despite two-drug treatment, and other
clinical clues suggestive of RAS, such as an abdominal
bruit and a sudden rise of a known blood pressure.
Clinical and biochemical data of these patients were col-
lected. Blood pressure was measured by using a standard
mercury sphygmomanometer with the patient supine.
The mean of three consecutive readings was used. The
possibility that these patients had other forms of second-
ary hypertension was assessed by determination of serum
electrolyte levels, plasma renin activity, aldosterone levels
and catecholamine levels. Urinary excretions of creatinine,
metanephrines and protein were also measured. Endo-
genous creatinine clearance was calculated from serum
creatinine level measurements [16]. The urine screenings,
together with microscopy of urine sediments were used
to exclude the possibility that these patients had
parenchymatous renal disease. Patients with other forms
of secondary hypertension and patients with renal in-
sufficiency were excluded from this study. For determi-
nation of plasma concentrations of active renin and
endothelin, venous blood was collected into tubes
containing EDTA. Samples were centrifuged immedi-
ately at 0° C and stored at - 20° C until assay. Active renin
and endothelin-1 levels were measured by radioim-
munoassays, as described previously [17,18]. The anti-
serum for endothelin-1 exhibited 67% cross-reactivity
with endothelin-2 and 84% with endothelin-3. PTRA was
performed as a standard procedure via the femoral
approach under direct high-resolution fluoroscopy. The
reactions of blood pressure to the procedure were deter-
mined according to the internationally accepted criteria.
A patient with blood pressure below 90 mmHg without
medication was considered cured. Improvement was
defined as a decline in blood pressure by at least 15%
with the same medication or a decline by 10% with
discontinuation of administration of at least one anti-
hypertensive drug. Patients who had been cured and
patients who had improved were placed in the success-
fully treated group and all patients with other outcomes
in the unsuccessfully treated group. A stenosis was consid-
ered significant if the vascular lumen was found by angio-
graphy to have narrowed by more than 50%. PTRA was
performed in patients with RAS for whom there was no
contra-indication to the treatment and who consented to
be subjected to the procedure. Patients were adminis-
tered 300 mg acetylsalicylic acid a day starting 1 day
before the procedure and continuing for 3 months after-
wards.
Statistical analysis
Values are expressed as medians (ranges) unless indicated
otherwise. Comparisons of the data within groups were
analysed by Wilcoxon’s paired signed rank test for para-
meters with non Gaussian distributions. Student’s paired
t test was used for parameters with normal distributions.
Differences between groups were assessed by unpaired
tests. When appropriate the Bonferroni correction for
multiple comparisons was applied. The correlations of
endothelin levels in members of the RAS, the primary
hypertension, the successfully treated and the unsuc-
cessfully treated groups either with renin level or with
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endogenous creatinine clearance were analysed by
Spearman’s rank correlation test. Statistical significance
was assumed at a 5% level, two-sided.
Results
Of the 52 patients with hypertension who had undergone
diagnostic digital subtraction angiography, 25 had no RAS
and were diagnosed as having essential hypertension. The
remaining 27 patients proved to have RAS. There were
20 unilateral and seven bilateral cases. The clinical char-
acteristics of the patients with and without RAS are
summarized in Table 1. The groups differed only in base-
line systolic blood pressure, that of the RAS group being
significantly higher than that of the group without stenosis
[186 mmHg (140–246) versus 168 mmHg (120–215),
P < 0.05]. Furthermore, atherosclerosis was the major aeti-
ological factor for RAS in our study rather than fibro-
muscular dysplasia (FMD, 20 versus seven patients).
Twenty-one of the 27 patients with RAS were treated by
PTRA of the stenosis. Of the 21 patients treated, 11
exhibited decreases in blood pressure in response to this
treatment. The remaining 10 patients did not respond to
this treatment. The clinical characteristics of these
patients are summarized in Table 1. Bilateral RAS was
found in patients in the unsuccessfully treated group more
often than it was in patients in the successfully treated
group (four versus one patient). Blood pressures of all
patients with FMD-related RAS responded to PTRA
treatment. Conversely, the unsuccessfully treated group
was comprised entirely of patients with RAS as a result
of atherosclerosis. The five patients with FMD RAS were
also the five women in the successfully treated group.
Thus, although male patients with atherosclerotic RAS
were distributed evenly between the successfully and
unsuccessfully treated groups, the female patients with
atherosclerotic RAS did not respond to treatment by
PTRA.
The baseline renin level in members of the RAS group
was significantly higher than that in members of the
essential hypertension group [40.2 mu/ml (0.9–543) and
13.4 mu/ml (2.5–931), respectively, P = 0.049]. The base-
line level of endothelin did not differ significantly
between RAS [3.6 pg/ml (1.4–11.7)] and essential hyper-
tension [5.0 pg/ml (1.5–8.0)] cases.
The baseline renin level in members of the successfully
treated group [25.7 mu/ml (9.2–475.6)] was not signifi-
cantly different from that in members of the unsuccess-
fully treated group [65.3 mu/ml (12.3–542.6)] and neither
were the baseline endothelin levels [3.6 pg/ml (1.8–8.9)
and 3.75 pg/ml (1.4–8.3), respectively].
ACE inhibition caused significant rises in active renin
levels in members both of the RAS and of the essential
hypertension group, [from 40.2 mu/ml (1–543) to
98.6 mu/ml (3.2–2004); P = 0.001 and from 13.4 mu/ml
(2.5–931) to 20.4 mu/ml (2.9–1432), P = 0.03, respectively].
In addition, the RAS patients who responded to treat-
ment by PTRA displayed a significant rise in renin levels
after ACE inhibition [from 25.7 mu/ml (9.2–475) to
72.8 mu/ml (10.4–2004), P = 0.001], whereas members of
the unsuccessfully treated group failed to respond to ACE
inhibition in terms of a significant rise in renin levels from
baseline [from 65.3 mu/ml (12.3–542.6) to 145 mu/ml
(11.3–1298)].
The differences (i.e. after- before values) in renin levels
before and after ACE inhibition did not differ significantly
between members of the RAS group [47.6 muml (- 28.5
to 1528) and members of the group with essential hyper-
tension [3.1 mu/ml (- 106 to 500)]. This also held true for
the successfully treated group [47 muml (- 2 to 1528) and
the unsuccessfully treated group [50 mu/ml (- 28 to 847)].
The relative differences between baseline values and
those after ACE inhibition were not significant for any of
the groups.
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Table 1 Clinical characteristics of hypertensive patients with or without renal artery stenosis, successfully
or unsuccessfully treated by percutaneous transluminal renal angioplasty
Renal artery Treatment Treatment 
No stenosis stenosis successful unsuccessful
(n = 25) (n = 27) (n = 11) (n = 10)
Men/women 13/12 15/12 6/5 6/4
Age (years) 48 (24–63) 52 (29–76) 48 (29–71) 55 (44–76)
Unilateral/bilateral stenosis 20/7 10/1 6/4
Aetiology: atherosclerosis/FMD 20/7* 6/5† 10/0
Baseline SBP (mmHg) 168 (120–215) 186 (140–246)‡ 180 (140–210) 197 (158–246)
Baseline DBP (mmHg) 101 (70–120) 108 (90–145) 108 (90–130) 109 (96–145)
BMI (kg/m2) 26.3 (17.8–43.0) 25.1 (17.6—39.6) 26.2 (19.1–30.5) 25.2 (21.6–29.6)
ECC (ml/min) 98.3 (26.4–256.2) 82.3 (23.2–153.3) 89.3 (45–153) 75.0 (32—134)
Smokers/non-smokers 12/13 14/13 7/4 5/5
With/without diabetes mellitus 1/1 1/0 0/0 0/0
Values are expressed as medians (ranges). FMD, fibromuscular dysplasia; SBP, systolic blood pressure; DBP, diastolic blood
pressure; BMI, body mass index; ECC, endogenous creatinine clearance. *No relation to the seven bilateral RAS patients. †All
FMD patients were women. ‡P < 0.05, versus no stenosis.
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The patients with essential hypertension had a baseline
endothelin level of 5.0 pg/ml (1.5–8.0) and the subjects
with RAS had a baseline endothelin level of 3.6 pg/ml
(1.4–1.7), which values were not significantly different
(Fig. 1). In members of the successful treatment group
baseline endothelin level was 3.6 pg/ml (1.8–8.9) and in
members of the unsuccessful group it was 3.75 pg/ml
(1.4–8.3); also these values were not significantly different
(Fig. 2).
ACE inhibition caused no significant change in endothelin
levels in members of any of the four study groups.
Furthermore, the differences and relative differences in
endothelin levels before and after ACE inhibition did not
differ significantly between members of the RAS group
and the essential hypertension group and between
members of the successfully and the unsuccessfully
treated groups.
The renin : endothelin level ratio at baseline was signi-
ficantly higher for the RAS group in comparison with 
that for the essential hypertension group [9.4 mu/pg
(0.1–131.5) versus 2.5 mu/pg (0.4–221.7), respectively,
P = 0.020]. ACE inhibition further increased the signifi-
cant difference between renin : endothelin level ratios for
the RAS and essential hypertension groups [26.5 mu/pg
(0.4–554.2) versus 3.6 mu/pg (0.5–227.3), respectively
P = 0.005].
The renin : endothelin level ratio at baseline was the same
for the group that responded as it was for the group that
did not respond to treatment by PTRA. Furthermore,
ACE inhibition failed to cause a significant difference
between values of this ratio for these patient groups. The
difference in ratios before and after ACE inhibition did
not differ significantly between the successfully and
unsuccessfully treated groups.
Endothelin levels in peripheral venous blood were not
correlated either to renin levels or to endogenous creati-
nine clearances for all four groups.
Discussion
The results of the present study indicate that endothelin
levels in peripheral venous blood under baseline resting
conditions are comparable among patients with essential
hypertension, hypertension combined with RAS and
RVH. In addition, ACE inhibition and thus a decrease in
Ang II levels did not affect endothelin levels in patients
with essential hypertension, patients with essential hyper-
tension combined with RAS and patients with RVH.
Although the renin : endothelin level ratio differed signif-
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Comparison of circulating endothelin levels in patients with hypertension before and after angiotensin converting enzyme (ACE) inhibition.
Horizontal bars, medians.
Fig. 1
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icantly between the groups with and without RAS, this
was largely, if not completely, due to the significant differ-
ence in renin levels. This argument also applies to the
renin : endothelin level ratio after ACE inhibition, which
displayed an even more significant difference.
In dividing the group of patients with RAS into those
who responded to PTRA and those who did not, we
attempted to distinguish between RAS leading to RVH
and RAS occurring concomitantly with essential hyper-
tension. Interestingly, among the patients with RAS,
administration of the ACE inhibitor caused renin levels
to rise only in members of the group who responded to
treatment by PTRA. Therefore, the fact that endothelin
levels did not differ between these groups and were not
affected differently by ACE inhibition makes the hypoth-
esis that endothelin plays a role in the pathophysiology
of RVH less plausible.
It is possible that the production and release of endothelin
were not affected during the relatively short 60 min
sampling period used in this study. However, an oral dose
of captopril reaches its maximum plasma level 1 h after
ingestion and the maximum blood-pressure-lowering
affect occurs 60–90 min after ingestion. Thus it can be
concluded that, 60 min after ingestion, while captopril is
affecting the renin–angiotensin system and other mechan-
isms involved in regulation of blood pressure, regulation
of endothelin production seems not to be altered.
Plasma levels of endothelin both in essential hypertension
and in RVH patients both with and without ACE inhi-
bition have been investigated by several other groups.
Results of most studies [12–15] concur with the results
of the present study. Two groups who studied endothelin
levels in blood samples taken directly from renal arteries
and veins found endothelin levels in healthy controls,
patients with essential hypertension and patients with
RAS to be within the normal range [14,15]. Januszewicz
et al. [19] reported that the degree of activation of the
renin–angiotensin system had no effect on the endothelin
levels, which were also not elevated in their patients with
RAS. In contrast, Giussani et al. [12] did find an increase
in plasma endothelin levels in patients with RAS and
elevated Ang II levels.
Several in-vitro studies with isolated arteries from rats and
humans have shown that the vasoconstricting effect of
infusion of endothelin-1 on vascular smooth muscle cells
is blunted in subjects with mild forms of hypertension
[19–21]. Furthermore, vascular smooth muscle cells from
spontaneous hypertensive rats display lower than normal
responses of intracellular calcium levels to infusion of
endothelin-1 but exhibit higher than normal responses to
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Comparison of circulating endothelin levels in patients for whom percutaneous transluminal renal angioplasty had been successful and
unsuccessful at lowering blood pressure before and after angiotensin converting enzyme (ACE). Horizontal bars, medians.
Fig. 2
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infusion of Ang II [22,23]. These results suggest that
endothelin does not affect vasoreactivity once hyper-
tension has been established and thus possibly this could
explain why endothelin levels are not elevated in most
hypertensive (patients with essential hypertension and
patients with RVH) subjects studied. Possibly endothelin
plays a role in vasoreactive events leading to chronic
hypertension. However, Sventek et al. [11] recently
showed that, although the one-kidney one clip Goldblatt
hypertensive rat exhibits vascular overexpression of the
endothelin-1 gene, the two-kidney, one clip Goldblatt
hypertensive rat only does so during a late phase. This
late expression could also be linked to renal failure or to
an inability of the lungs or kidneys to clear the endothelin.
Thus, although many studies, including the present one,
could not show that circulating endothelin plays a role in
maintaining RVH, endothelin’s role in the early phase of
RVH has yet to be sufficiently studied.
With the exception of baseline systolic blood pressure,
there were no significant differences among the clinical
characteristics of the groups studied. Male and female
patients were distributed equally among groups. In a
recent study [24] it was found that plasma endothelin
levels are modulated by the menstrual cycle. Although
this new knowledge does not directly affect the results
of the present study, all future studies of this type should
take the effect of the menstrual cycle on endothelin 
levels into consideration when experimenting on female
subjects. Of the 27 patients with RAS, seven were diag-
nosed as having bilateral stenosis. Furthermore, four of
the unsuccessfully and one of the successfully treated
patients had bilateral RAS. In such cases, both renal
arteries were treated by PTRA. It was, however, beyond
the scope of this study to evaluate the difference between
unilateral and bilateral stenosis with regard to hyper-
tension, renin levels and endothelin levels.
In conclusion, the present study showed that circulating
levels of endothelin in patients with essential hyper-
tension, patients with hypertension with RAS and patients
with true RVH are similar. Although the renin–
angiotensin system in patients with RVH was activated,
as shown by a significant increase in plasma renin activity
after ACE inhibition, endothelin levels were not corre-
lated to the renin levels and were not affected by ACE
inhibition. These results do not support the hypothesis
that production of endothelin in RVH patients is depen-
dent on Ang II.
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